» Articles » PMID: 37373347

Effect of 12-Week BMI-Based Vitamin D Supplementation in Parkinson's Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Jun 28
PMID 37373347
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease. To manage motor symptoms not controlled adequately with medication, deep brain stimulation (DBS) is used. PD patients often manifest vitamin D deficiency, which may be connected with a higher risk of falls. We administered a 12-week vitamin D supplementation based on BMI (with higher doses given to patients with higher BMI) to investigate its effects on physical performance and inflammation status in PD patients with DBS. Patients were randomly divided into two groups: treated with vitamin D (VitD, = 13), and supplemented with vegetable oil as the placebo group (PL, = 16). Patients underwent functional tests to assess their physical performance three times during this study. The serum 25(OH)D concentration increased to the recommended level of 30 ng/mL in the VitD group, and a significant elevation in vitamin D metabolites in this group was found. We observed significant improvement in the Up and Go and the 6 MWT in the VitD group. In inflammation status, we noticed a trend toward a decrease in the VitD group. To conclude, achieving the optimal serum 25(OH)D concentration is associated with better functional test performance and consequently may have a positive impact on reducing falling risk in PD.

Citing Articles

The U-shaped correlation between serum VD concentration and systemic immune-inflammatory index: results from the NHANES database prospective cohort study.

Yunpeng P, Shangnan D, Di W, Chaoqun H, Wanli G, Qiang L BMC Public Health. 2024; 24(1):3570.

PMID: 39716133 PMC: 11665119. DOI: 10.1186/s12889-024-21133-0.


Functional Food Nutrients, Redox Resilience Signaling and Neurosteroids for Brain Health.

Scuto M, Majzunova M, Torcitto G, Antonuzzo S, Rampulla F, Di Fatta E Int J Mol Sci. 2024; 25(22).

PMID: 39596221 PMC: 11594618. DOI: 10.3390/ijms252212155.


Vitamin D supplementation in later life: a systematic review of efficacy and safety in movement disorders.

Homann C, Homann B, Ivanic G, Urbanic-Purkart T Front Aging Neurosci. 2024; 16:1333217.

PMID: 38343878 PMC: 10853433. DOI: 10.3389/fnagi.2024.1333217.


Targeting neuroendocrine abnormalities in Parkinson's disease with exercise.

Luthra N, Christou D, Clow A, Corcos D Front Neurosci. 2023; 17:1228444.

PMID: 37746149 PMC: 10514367. DOI: 10.3389/fnins.2023.1228444.


Impact of 12 Weeks of Vitamin D Administration in Parkinson's Patients with Deep Brain Stimulation on Kynurenine Pathway and Inflammatory Status.

Bytowska Z, Korewo-Labelle D, Kowalski K, Libionka W, Przewlocka K, Kloc W Nutrients. 2023; 15(17).

PMID: 37686871 PMC: 10490466. DOI: 10.3390/nu15173839.

References
1.
Barichella M, Cereda E, Iorio L, Pinelli G, Ferri V, Cassani E . Clinical correlates of serum 25-hydroxyvitamin D in Parkinson's disease. Nutr Neurosci. 2020; 25(6):1128-1136. DOI: 10.1080/1028415X.2020.1840117. View

2.
Walsh J, Bowles S, Evans A . Vitamin D in obesity. Curr Opin Endocrinol Diabetes Obes. 2017; 24(6):389-394. DOI: 10.1097/MED.0000000000000371. View

3.
Dedeckova E, Vitak R, Jirasko M, Kralova M, Topolcan O, Pecen L . Vitamin D Supplementation: Comparison of 1000 IU and 2000 IU Dose in Healthy Individuals. Life (Basel). 2023; 13(3). PMC: 10053989. DOI: 10.3390/life13030808. View

4.
Lawton M, Baig F, Toulson G, Morovat A, Evetts S, Ben-Shlomo Y . Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort. Mov Disord. 2019; 35(2):279-287. PMC: 7028059. DOI: 10.1002/mds.27888. View

5.
Koduah P, Paul F, Dorr J . Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. EPMA J. 2017; 8(4):313-325. PMC: 5700019. DOI: 10.1007/s13167-017-0120-8. View